Clinical perspectives on hereditary hemochromatosis

Critical Reviews in Clinical Laboratory Sciences

Volumn 45, Issue 5, 2008, Pages 451-484

  Ayonrinde, Oyekoya T ^a,b   Milward, Elizabeth A ^c   Chua, Anita C G ^a   Trinder, Debbie ^a,d   Olynyk, John K ^a,b,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cancer; Cirrhosis; Clinical expression; Genotype; Hemochromatosis; Hepatic iron concentration; Hepcidin; HFE; Iron; Liver; Phenotype; Screening

Indexed keywords

ASCORBIC ACID; CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERROPORTIN; HEPCIDIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR 2;

ADULTHOOD; ANEMIA; ARTHRITIS; BIOCHEMISTRY; CARDIOMYOPATHY; CHRONIC LIVER DISEASE; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEART ARRHYTHMIA; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LIVER; LIVER BIOPSY; LIVER INJURY; MASS SCREENING; METABOLIC REGULATION; MORBIDITY; MORTALITY; NEOPLASM; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TRANSFERRIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

GENOTYPE; HEMOCHROMATOSIS; HOMEOSTASIS; HUMANS; IRON; PHENOTYPE;

EID: 49949091638     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.1080/10408360802335716     Document Type: Review

References (218)

1. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005; 100: 837-841.
2. Adams PC. Review article: the modern diagnosis and management of haemochromatosis. Aliment Pharmacol Ther 2006; 23: 1681-1691.
3. Siah CW, Trinder D, Olynyk JK. Iron overload. Clin Chim Acta 2005; 358: 24-36.
4. Bomford A. Genetics of haemochromatosis. Lancet 2002; 360: 1673-1681.
5. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
6. Chua ACG, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci 2007; 44: 413-459.
7. Parkkila S, Waheed A, Britton RS, Feder JN, Tsuchihashi Z, Schatzman RC, Bacon BR, Sly WS. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA 1997; 94: 2534-2539.
8. Bastin JM, Jones M, O'Callaghan CA, Schimanski L, Mason DY, Townsend ARM. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Br Haematol 1998; 103: 931-941.
9. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147-150.
10. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
11. Kawabata H, Yang S, Hirama T, Vuong PT, Kawano S, Gombart AF, Koeffler HP. Molecular cloning of transferrin receptor 2 - A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826-20832.
12. West AP, Bennett MJ, Sellers VM, Andrews NC, Enns CA, Bjorkman PJ. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem 2000; 275: 38135-38138.
13. Robb AD, Ericsson M, Wessling-Resnick M. Transferrin receptor 2 mediates a biphasic pattern of transferrin uptake associated with ligand delivery to multivesicular bodies. Am J Physiol Cell Physiol 2004; 287: C1769-C1775.
14. Krijt J, Vokurka M, Chang KT, Necas E. Expression of Rgmc, the murine ortholog of hemojuvelin gene, is modulated by development and inflammation, but not by iron status or erythropoietin. Blood 2004; 104: 4308-4310.
15. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, Andrews NC, Lin HY. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-539.
16. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008; 15: 169-175.
17. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-19912.
18. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781.
19. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299-309.
20. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
21. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-724.
22. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol 2000; 32: 48-62.
23. Powell LW, Dixon JL, Ramm GA, Purdie DM, Lincoln DJ, Anderson GJ, Subramaniam VN, Hewett DG, Searle JW, Fletcher LM, Crawford DH, Rodgers H, Allen KJ, Cavanaugh JA, Bassett ML. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166: 294-301.
24. Brissot P, Hitadenercy Y, Pawlotsky Y, Simon M, Bourel M. Biology of idiopathic hemochromatosis - Without quantitative hormone determination. Rev Med 1977; 18: 835.
25. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by Family HLA typing. N Engl J Med 1977; 297: 1017-1021.
26. Pietrangelo A. Hereditary hemochromatosis - A new look at an old disease. N Engl J Med 2004; 350: 2383-2397.
27. Jazwinska EC, Cullen LM, Busfield F, Pyper WR, Webb SI, Powell LW, Morris CP, Walsh TP. Haemochromatosis and HLA-H. Nat Genet 1996; 14: 249-251.
28. Brissot P, Moirand R, Jouanolle AM, Guyader D, Le Gall JY, Deugnier Y, David V. A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria. J Hepatol 1999; 30: 588-593.
29. The UK Haemochromatosis Consortium W. M. A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997; 41: 841-844.
30. Piperno A, Sampietro M, Pietrangelo A, Arosio C, Lupica L, Montosi G, Vergani A, Fraquelli M, Girelli D, Pasquero P, Roetto A, Gasparini P, Fargion S, Conte D, Camaschella C. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114: 996-1002.
31. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-278.
32. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778.
33. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93: 2502-2505.
34. de Villiers JN, Hillermann R, Loubser L, Kotze MJ. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum Mol Genet 1999; 8: 1517-1522.
35. Barton JC, Rothenberg BE, Bertoli LF, Acton RT. Diagnosis of hemochromatosis in family members of probands: a comparison of phenotyping and HFE genotyping. Genet Med 1999; 1: 89-93.
36. Salvioni A, Mariani R, Oberkanins C, Moritz A, Mauri V, Pelucchi S, Riva A, Arosio C, Cerutti P, Piperno A. Prevalence of C282Y and E168X HFE mutations in an Italian population of Northern European ancestry. Haematologica 2003; 88: 250-255.
37. Pietrangelo A. Non-HFE hemochromatosis. Semin Liver Dis 2005; 25: 450-460.
38. Camaschella C. Juvenile haemochromatosis. Baillieres Clinical Gastroenterology 1998; 12: 227-235.
39. Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, Simard R, D'Adamo AP, Ferec C, Camaschella C, Mura C, Roetto A, De Braekeleer M, Bechner L, Gasparini P. Juvenile hemochromatosis locus maps to chromosome 1q in a French Canadian population. Eur J Hum Genet 2003; 11: 585-589.
40. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald MLE, Franchini PL, Dube MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Davidas O, Christakis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
41. Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-22.
42. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
43. De Gobbi M, Barilaro MR, Garozzo G, Sbaiz L, Alberti F, Camaschella C. TFR2 Y250X mutation in Italy. Br J Haematol 2001; 114: 243-244.
44. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, Cali A, De Gobbi M, Gasparini P, Camaschella C. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97: 2555-2560.
45. Girelli D, Bozzini C, Roetto A, Alberti F, Daraio F, Colombari R, Olivieri O, Corrocher R, Camaschella C. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122: 1295-1302.
46. Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, Butterfield Y, Rodrigues P, Jones S, Porto G, Marra M, De Sousa M, Vatcher G. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002; 100: 1075-1077.
47. Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004; 125: 674-678.
48. Koyama C, Wakusawa S, Hayashi H, Suzuki R, Yano M, Yoshioka K, Kozuru M, Takayamam Y, Okada T, Mabuchi H. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica 2005; 90: 302-307.
49. Kawabata H, Fleming RE, Gui D, Moon SY, Saitoh T, O'Kelly J, Umehara Y, Wano Y, Said JW, Koeffler HP. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005; 105: 376-381.
50. Drake SF, Morgan EH, Herbison CE, Delima R, Graham RM, Chua ACG, Leedman PJ, Fleming RE, Bacon BR, Olynyk JK, Trinder D. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3. Am J Physiol Gastrointest Liver Physiol 2007; 292: G323-G328.
51. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood 2005; 105: 1803-1806.
52. Jouanolle AM, Douabin-Gicquel V, Halimi C, Loreal O, Fergelot P, Delacour T, de Lajarte-Thirouard AS, Turlin B, Le Gall JY, Cadet E, Rochette J, David V, Brissot P. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol 2003; 39: 286-289.
53. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619-623.
54. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JWF, Breuning MH, Snijders P, Rutten WPF, Sandkuijl LA, Oostra BA, van Duijn CM, Heutink P. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213-214.
55. Arden KE, Wallace DF, Dixon JL, Summerville L, Searle JW, Anderson GJ, Ramm GA, Powell LW, Subramaniam VN. A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient. Gut 2003; 52: 1215-1217.
56. Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 2003; 102: 1904-1910.
57. Beutler E, Barton JC, Felitti VJ, Gelbart T, West C, Lee PL, Waalen J, Vulpe C. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305-309.
58. Bach V, Remacha A, Altes A, Barcelo MJ, Molina MA, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol Dis 2005; 36: 41-45.
59. Wallace DF, Browett P, Wong P, Kua H, Ameratunga R, Subramaniam VN. Identification of ferroportin disease in the Indian subcontinent. Gut 2005; 54: 567-568.
60. Devalia V, Carter K, Walker AP, Perkins SJ, Worwood M, May A, Dooley JS. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100: 695-697.
61. Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis 2005; 34: 157-161.
62. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 2005; 105: 4096-4102.
63. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89: 739-761.
64. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, Brittenham G, Pippard MJ, Finch CA. The effect of erythroid hyperplasia on iron balance. Blood 1988; 71: 1124-1129.
65. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341: 99-109.
66. Nemeth E, Ganz T. Hepcidin and iron-loading anemias. Haematologica 2006; 91: 727-732.
67. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92: 583-588.
68. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.
69. Hanspeter N. Iron chelation, quo vadis? Curr Opin Chem Biol 2007; 11: 419-423.
70. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev 2005; 4: CD004450.
71. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436-3441.
72. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: A clinical review. Clin Ther 2007; 29: 2154-2166.
73. Hershko C. Iron loading and its clinical implications. Am J Hematol 2007; 82: 1147-1148.
74. Yang LPH, Keam SJ, Keating GM. Deferasirox - A review of its use in the management of transfusional chronic iron overload. Drugs 2007; 67: 2211-2230.
75. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, Goldberg YP, Sakellaropoulos N, Ganz T, Nemeth E. Hepcidin in iron overload disorders. Blood 2005; 105: 4103-4105.
76. Adamsky K, Weizer O, Amariglio N, Breda L, Harmelin A, Rivella S, Rachmilewitz E, Rechavi G. Decreased hepcidin mRNA expression in thalassemic mice. Br J Haematol 2004; 124: 123-124.
77. Bothwell TH. Overview and mechanisms of iron regulation. Nutr Rev 1995; 53: 237-245.
78. Gordeuk V, Mukiibi J, Hasstedt Sj, Samowitz W, Edwards CQ, West G, Ndambire S, Emmanual J, Nkanza N, Chapanduka Z, Randall M, Boone P, Romano P, Martell Rw, Yamashita T, Effler P, Brittenham G. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95-100.
79. Brink B, Disler P, Lynch S, Jacobs P, Charlton R, Bothwell T. Patterns of iron storage in dietary iron overload and idiopathic hemochromatosis. J Lab Clin Med 1976; 88: 725-731.
80. McNamara L, MacPhail AP, Gordeuk VR, Hasstedt SJ, Rouault T. Is there a link between African iron overload and the described mutations of the hereditary haemochromatosis gene? Br J Haematol 1998; 102: 1176-1178.
81. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, Onyekwere O, Kittles R, Pignatti E, Montosi G, Garuti C, Gangaidzo IT, Gomo ZA, Moyo VM, Rouault TA, MacPhail P, Pietrangelo A. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31: 299-304.
82. McNamara L, Gordeuk VR, MacPhail AP. Ferroportin (Q248H) mutations in African families with dietary iron overload. J Gastroenterol Hepatol 2005; 20: 1855-1858.
83. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997; 112: 882-888.
84. Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology 2008; 134: 348-351.
85. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005; 25: 433-449.
86. Batey RG, Johnston R. Effects of alcohol, carbon-tetrachloride, and choline deficiency on iron-metabolism in the rat. Alcohol Clin Exp Res 1993; 17: 931-934.
87. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-1109.
88. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000; 32: 135-138.
89. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, Kobune M, Takada K, Takimoto R, Hamada H, Ikeda T, Niitsu Y. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69: 191-197.
90. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27: 243-250.
91. Goya N, Miyazaki S, Kodate S, Ushio B. A family of congenital atransferrinemia. Blood 1972; 40: 239-245.
92. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood 2000; 96: 4071-4074.
93. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995; 92: 2539-2543.
94. Hellman NE, Schaefer M, Gehrke S, Stegen P, Hoffman WJ, Gitlin JD, Stremmel W. Hepatic iron overload in aceruloplasminaemia. Gut 2000; 47: 858-860.
95. Becker EM, Greer JM, Ponka P, Richardson DR. Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization. Blood 2002; 99: 3813-3822.
96. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2006; 145: 209-223.
97. Ayonrinde OT, Olynyk JK. Clinical expression of hemochromatosis gene (HFE) variants. Hepatology 2007; 46: 960-962.
98. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990; 74: 525-530.
99. Waalen J, Beutler E. Beware of multiple comparisons: a study of symptoms associated with mutations of the HFE hemochromatosis gene. Clin Chim Acta 2005; 361: 128-134.
100. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, Yip R. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 1999; 106: 619-624.
101. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-1328.
102. Delatycki MB, Powell LW, Allen KJ. Hereditary hemochromatosis genetic testing of at-risk children: what is the appropriate age? Genet Test 2004; 8: 98-103.
103. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G - A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
104. Asberg A, Hveem K, Thorstensen K, Ellekjaer E, Kannelonning K, Fjosne U, Halvorsen TB, Smethurst HBG, Sagen E, Bjerve KS. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36: 1108-1115.
105. McCune CA, Al-Jader LN, May A, Hayes SL, Jackson HA, Worwood M. Hereditary haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002; 111: 538-543.
106. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-230.
107. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-29.
108. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002; 122: 281-289.
109. Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW. Effect of hemochromatosis genotype and lifestyle factors on iron and red cell indices in a community population. Clin Chem 2001; 47: 202-208.
110. McCune CA, Ravine D, Carter K, Jackson HA, Hutton D, Hedderich J, Krawczak M, Worwood M. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 2006; 55: 554-562.
111. Milward EA Baines SK, Knuiman MW, Bartholomew HC, Divitini ML, Ravine DG, Bruce DG, Olynyk JK. Non-citrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin Proc 2008; 83: 543-549.
112. Powell LW, Jazwinska E, Halliday J. Changing concepts of haemochromatosis. Adv Exp Med Biol 1994; 356: 285-291.
113. Milman N. Serum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. Int J Hematol 1996; 63: 103-135.
114. Willis G, Bardsley V, Fellows IW, Lonsdale R, Wimperis JZ, Jennings BA. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol 2005; 5: 17.
115. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-1119.
116. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953-962.
117. Crawford DHG, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, Jeffrey GP, McCaughan GW, Kerlin P, Powell LW, Elias EE. Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 2004; 39: 1655-1662.
118. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol 2001;96: 567-569.
119. Axford JS. Rheumatic manifestations of haemochromatosis. Baillieres Clin Rheumatol 1991; 5: 351-365.
120. Faraawi R, Harth M, Kertesz A, Bell D. Arthritis in hemochromatosis. J Rheumatol 1993; 20: 448-452.
121. Olynyk J, Hall P, Ahern M, Kwiatek R, Mackinnon M. Screening for genetic haemochromatosis in a rheumatology clinic. Aust N Z J Med 1994; 24: 22-25.
122. Willis G, Scott DGI, Jennings BA, Smith K, Bukhari M, Wimperis JZ. HFE mutations in an inflammatory arthritis population. Rheumatology (Oxford) 2002; 41: 176-179.
123. Sherrington CA, Knuiman MW, Divitini ML, Bartholomew HC, Cullen DJ, Olynyk JK. Population-based study of the relationship between mutations in the hemochromatosis (HFE) gene and arthritis. J Gastroenterol Hepatol 2006; 21: 595-598.
124. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343: 1529-1535.
125. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial-infarction in eastern Finnish men. Circulation 1992; 86: 803-811.
126. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation - A prospective cohort study in men in eastern Finland. Circulation 1999; 100: 1274-1279.
127. Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary-artery disease. JAMA 1994;272: 231-233.
128. Franco RF, Zago MA, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJP, Reitsma PH. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haematol 1998; 102: 1172-1175.
129. Fox CJ, Cullen DJ, Knuiman MW, Cumpston GN, Divitini ML, Rossi E, Gochee PA, Powell LW, Olynyk JK. Effects of body iron stores and haemochromatosis genotypes on coronary heart disease outcomes in the Busselton health study. J Cardiovasc Risk 2002; 9: 287-293.
130. Porto I, Leone AM, Crea F, Andreotti F. Inflammation, genetics, and ischemic heart disease: focus on the major histocompatibility complex (MHC) genes. Cytokine 2005; 29: 187-196.
131. van der AD, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-Renaud JH, Breuer W, Cabantchik ZI, Roest M, Voorbij HA, van der Schouw YT. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation 2006;113: 1942-1949.
132. Mandelli C, Cesarini L, Piperno A, Fargion S, Fracanzani AL, Barisani D, Conte D. Saturability of hepatic iron deposits in genetic hemochromatosis. Hepatology 1992; 16: 956-959.
133. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 162-166.
134. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis- associated mortality in the United States from 1979 to 1992: an analysis of multiple-cause mortality data. Ann Intern Med 1998; 129: 946-953.
135. Ptaszek LM, Price ET, Hu MY, Yang PC. Early diagnosis of hemochromatosis-related cardiomyopathy with magnetic resonance imaging. J Cardiovasc Magn Reson 2005; 7: 689-692.
136. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2*cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23: 662-668.
137. Sechtem U, Mahrholdt H, Vogelsberg H. Cardiac magnetic resonance in myocardial disease. Heart 2007; 93: 1520-1527.
138. DuBois S, Kowdley KV. Review article. Targeted screening for hereditary haemochromatosis in high-risk groups. Aliment Pharmacol Ther 2004; 20: 1-14.
139. Dabestani A, Child JS, Perloff JK, Figueroa WG, Schelbert HR, Engel TR. Cardiac abnormalities in primary hemochromatosis. Ann NY Acad Sci 1988; 526: 234-244.
140. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-681.
141. Albright ES, Bell DSH. The liver, liver disease and diabetes mellitus. Endocrinologist 2003; 13: 58-66.
142. Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M, Corsetti M, Fraquelli M. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998; 128: 370-373.
143. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, Petersen P, Schlichting P, Saermark T, Tybjaerg-Hansen A, Birgens H. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 1405-1409.
144. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, Kushner JP. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 2006; 49: 1661-1669.
145. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-2919.
146. Waalen J, Nordestgaard BG, Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 2005; 18: 203-220.
147. Acton RT, Reboussin DM, Barton JC, McLaren GD, Passmore LV, Harris EL, Adams PC, Bent TC, Speechley MR, Vogt TM, Castro O, Sholinsky P. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the hemochromatosis and iron overload screening (HEIRS) study. Diabetes Care 2006; 29: 2084-2089.
148. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46: 1071-1080.
149. Halsall DJ, McFarlane I, Luan J, Cox TM, Wareham NJ. Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case-control study. Hum Mol Genet 2003; 12: 1361-1365.
150. Dubois-Laforgue D, Larger E, Timsit J. Is diabetes mellitus a sufficient condition to suspect hemochromatosis? Diabetes Metab 2000; 26: 318-321.
151. Sampson MJ, Williams T, Heyburn PJ, Greenwood RH, Temple RC, Wimperis JZ, Jennings BA, Willis GA. Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 2000; 135: 170-173.
152. Youdim MB, Yehuda S. The neurochemical basis of cognitive deficits induced by brain iron deficiency: involvement of dopamine-opiate system. Cell Mol Biol (Noisy-le-grand) 2000; 46: 491-500.
153. Ke Y, Qian ZM. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003; 2: 246-253.
154. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-873.
155. Pinero DJ, Hu J, Connor JR. Alterations in the interaction between Fe regulatory proteins and their Fe responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol (Noisy-le-grand) 2000; 46: 761-776.
156. Connor JR, Milward EA, Moalem S, Percy M, Sampietro M, Vergani C, Scott RJ, Chorney M. Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimers Dis 2001; 3: 471-477.
157. Senior K. New genes reveal major role for iron in neurodegeneration. Lancet 2001; 358: 302.
158. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28: 350-354.
159. Crompton DE, Chinnery PF, Fey C, Curtis ARJ, Morris CM, Kierstan J, Burt A, Young F, Coulthard A, Curtis A, Ince PG, Bates D, Jackson MJ, Burn J. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol Dis 2002; 29: 522-531.
160. Xu X, Pin S, Gathinji M, Fuchs R, Harris ZL. Aceruloplasminemia. An inherited neurodegenerative disease with impairment of iron homeostasis. Ann NY Acad Sci 2004; 1012: 299-305.
161. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz
162. Bhidayasiri R, Perlman SL, Pulst SM, Geschwind DH. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch Neurol 2005; 62: 1865-1869.
163. Berg D, Hoggenmuller U, Hofmann E, Fischer R, Kraus M, Scheurlen M, Becker G. The basal ganglia in haemochromatosis. Neuroradiology 2000; 42: 9-13.
164. Moos T, Morgan EH. Transferrin and receptor function in brain barrier systems. Cell Mol Neurobiol 2000; 20: 77-95.
165. Moos T, Morgan EH. A morphological study of the developmentally regulated transport of iron into the brain. Dev Neurosci 2002; 24: 99-105.
166. Deane R, Zheng W, Zlokovic BV. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem 2004; 88: 813-820.
167. Bastin JM, Jones M, O'Callaghan CA, Schimanski L, Mason DY, Townsend AR. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Br J Haematol 1998; 103: 931-941.
168. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997; 94: 9866-9868.
169. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, Mintz J. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 2000; 57: 47-53.
170. Blacker D, Bertram L, Saunder AJ, Moscarillo TJ, Albert MS, Weiner H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney AJ, Beaty T, M.D. F, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE. Results of a high resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 2003; 12: 1723-1732.
171. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 48-53.
172. Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet 2000; 93: 58-66.
173. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging 2001; 22: 563-568.
174. Lleó A, Blesa R, Angelopoulos C, Pastor-Rubio P, Villa M, Oliva R, Bufill E. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 820-821.
175. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM. Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging 2004; 25: 465-474.
176. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, Ribeiro MH, Hardy J, Singleton A, Oliveira C. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol 2006; 6: 24-31.
177. Golub MS, Germann SL, Araiza RS, Reader JR, Griffey SM, Lloyd KCK. Movement disorders in the Hfe knockout mouse. Nutr Neurosci 2005; 8: 239-244.
178. Martinez di Montemuros F, Tavazzi D, Salsano E, Piepoli T, Pollo B, Fiorelli G, Finocchiaro G. High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. Neurology 2001; 57: 1342.
179. Chapman C, Johnson L, Marriott M, Mraz G, Tait B, Wilkinson C, Taylor B, Speed TP, Foote SJ, Kilpatrick TJ. Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Hum Genet 2004; 114: 573-580.
180. Haba-Rubio J, Staner L, Petiau C, Erb G, Schunck T, Macher JP. Restless legs syndrome and low brain iron levels in patients with haemochromatosis. J Neurol Neurosurg Psychiatry 2005; 76: 1009-1010.
181. Stovner LJ, Hagen K, Waage A, Bjerve KS. Hereditary haemochromatosis in two cousins with cluster headache. Cephalgia 2002; 22: 317-319.
182. Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH. HFE mutations are not strongly associated with sporadic ALS. Neurology 2004; 62: 1611-1612.
183. Beckman LE, Van Landeghem GF, Sikstrom C, Wahlin A, Markevarn B, Hallmans G, Lenner P, Athlin L, Stenling R, Beckman L. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 1999; 20: 1231-1233.
184. Fuchs J, Podda M, Packer L, Kaufmann R. Morbidity risk in HFE associated hereditary hemochromatosis C282Y heterozygotes. Toxicology 2002; 180: 169-181.
185. Kallianpur AR, Hall LD, Yadav M, Christman BW, Dittus RS, Haines JL, Parl FF, Summar ML. Increased prevalence of the HFE C282Y hemochromatosis allele in women with breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 205-212.
186. Abraham BK, Justenhoven C, Pesch B, Harth V, Weirich G, Baisch C, Rabstein S, Ko YD, Bruning T, Fischer HP, Haas S, Brod S, Oberkanins C, Hamann U, Brauch H. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1102-1107.
187. McGlynn KA, Sakoda LC, Hu Y, Schoen RE, Bresalier RS, Yeager M, Chanock S, Hayes RB, Buetow KH. Hemochromatosis gene mutations and distal adenomatous colorectal polyps. Cancer Epidemiol Biomarkers Prev 2005; 14: 158-163.
188. Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, Nisselle AE, Fletcher AR, McLaren CE, English DR, Hopper JL, Giles GG, Olynyk J, Nicoll A, Powell LW, Gertig DM. Homozygosity for the C282Y mutation in the HFE gene is associated with increased risk of colorectal and breast cancer in Australian population. Am J Hematol 2007; 82: 575.
189. Dorak MT, Burnett AK, Worwood M. HFE gene mutations in leukemia: HuGE review susceptibility to childhood. Genet Med 2005; 7: 159-168.
190. Rossi E, Wallace DF, Subramaniam VN, St Pierre TG, Mews C, Jeffrey GP. Clinical expression of C282Y homozygous HFE hemochromatosis at 14 years of age. Ann Clin Biochem 2006; 43: 233-236.
191. Van Aken MO, De Craen AJ, Gussekloo J, Moghaddam PH, Vandenbroucke JP, Heijmans BT, Slagboom PE, Westendorp RG. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus study. Eur J Clin Invest 2002; 32: 750-754.
192. Willis G, Wimperis JZ, Smith K, Fellows IW, Jennings BA. HFE mutations in the elderly. Blood Cells Mol Dis 2003; 31: 240-246.
193. Rossi E, Olynyk JK, Cullen DJ, Papadopoulos G, Bulsara M, Summerville L, Powell LW. Compound heterozygous hemochromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000; 46: 162-166.
194. Geier A, Gartung C, Theurl I, Weiss G, Lammert F, Dietrich CG, Weiskirchen R, Zoller H, Hermanns B, Matern S. Occult celiac disease prevents penetrance of hemochromatosis. World J Gastroenterol 2005; 11: 3323-3326.
195. McLaren CE, McLachlan GJ, Halliday JW, Webb SI, Leggett BA, Jazwinska EC, Crawford DH, Gordeuk VR, McLaren GD, Powell LW. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 1998; 114: 543-549.
196. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 2001; 120: 718-725.
197. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111: 3373-3376.
198. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Wihttall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 2004; 79: 309-313.
199. Adams PC, Reboussin DM, Leiendecker-Foster C, Moses GC, McLaren GD, McLaren CE, Dawkins FW, Kasvosve I, Acton RT, Barton JC, Zaccaro D, Harris EL, Press R, Chang H, Eckfeldt JH. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin Chem 2005; 51: 1048-1052.
200. Vartsky D, Ellis KJ, Hull DM, Cohn SH. Nuclear resonant scattering ofgammarays - A new technique for in vivo measurement of body iron stores. Phys Med Biol 1979; 24: 689-701.
201. Leung AW, Steiner RE, Young IR. Nmr imaging of the liver in 2 cases of iron overload. J Comput Assist Tomogr 1984; 8: 446-449.
202. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-19.
203. Alustiza JM, Artetxe J, Castiella A, Agirre C, Emparanza JI, Otazua P, Garcia-Bengoechea M, Barrio J, Mujica F, Recondo JA. MR quantification of hepatic iron concentration. Radiology 2004;230: 479-484.
204. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-861.
205. Gandon Y, Olivie D, Guyader D, Aube C, Oberti F, Sebille V, Deugnier Y. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-362.
206. Guyader D, Jacquelinet C, Moirand R, Turlin B, Mendler MH, Chaperon J, David V, Brissot P, Adams P, Deugnier Y. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-936.
207. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol 2000; 95: 1788-1793.
208. Kent G, Popper H. Liver biopsy in diagnosis of hemochromatosis. Am J Med 1968; 44: 837-841.
209. Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003; 349: 562-569.
210. Pollitz K, Peshkin BN, Bangit E, Lucia K. Genetic discrimination in health insurance: current legal protections and industry practices. Inquiry 2007; 44: 350-368.
211. Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N, Adams PC, Barton JC, Beutler E, Brittenham G, Buchanan A, Clayton EW, Cogswell ME, Meslin EM, Motulsky AG, Powell LW, Sigal E, Wilfond BS, Collins FS. Hereditary hemochromatosis - Gene discovery and its implications for population-based screening. JAMA 1998; 280: 172-178.
212. Alper JS, Geller LN, Barash CI, Billings PR, Laden V, Natowicz MR. Genetic discrimination and screening for hemochromatosis. J Public Health Policy 1994; 15: 345-358.
213. Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing. Lancet 2002; 359: 1433.
214. Delatycki MB, Allen KJ, Nisselle AE, Collins V, Metcalfe S, du Sart D, Halliday J, Aitken MA, Macciocca I, Hill V, Wakefield A, Ritchie A, Gason AA, Nicoll AJ, Powell LW, Williamson R. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-316.
215. Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001;5: 107-110.
216. Kaltwasser JP, Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998; 43: 699-704.
217. Yu L, Ioannou GN. Survival of liver transplant recipients with hemochromatosis in the United States. Gastroenterology 2007; 133: 489-495.
218. Schumacher HR, Straka PC, Krikker MA, Dudley AT. The arthropathy of hemochromatosis - recent Studies. Ann NY Acad Sci 1988; 526: 224-233.